title: Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.
abstract: The purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice. NISV were prepared by lipid film hydration method. The mean diameter of vesicles was around 390 nm for DTK-containing NISV (DTK-NISV) and 320 nm for gB1s-containing NISV (gB1s-NISV). The encapsulation efficiency of the molecules was comprised between 57% and 70%. After 7-14 day NISV maintained stable dimensions and a drug encapsulation higher than 48%. We showed that intranasal immunization with gB1s-NISV induces gB-specific IgG antibody and lymphoproliferative responses, whereas vaccination with DTK-NISV was not able to generate a gB-specific immune response. Our results indicate that vaccination of BALB/c mice with gB1s-NISV induced Th1 responses, as characterized by increased titre of IG2a in plasma and IFN-production in CD4+ splenic cells. Intranasal immunization with gB1s-NISV could elicit 90% (almost complete) protection against a heterologous lethal vaginal challenge with herpes simplex virus type 2. These data may have implications for the development of a mucosal vaccine against genital herpes.
authors: Department of Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy. crt@unife.it
authors: Rita
authors: R
authors: Cortesi
authors: Laura
authors: L
authors: Ravani
authors: Francesca
authors: F
authors: Rinaldi
authors: Peggy
authors: P
authors: Marconi
authors: Markus
authors: M
authors: Drechsler
authors: Marco
authors: M
authors: Manservigi
authors: Rafaela
authors: R
authors: Argnani
authors: Enea
authors: E
authors: Menegatti
authors: Elisabetta
authors: E
authors: Esposito
authors: Roberto
authors: R
authors: Manservigi
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002522:Chlorocebus aethiops; D016207:Cytokines / Q000378:metabolism; D029721:Drosophila Proteins / Q000008:administration & dosage / Q000276:immunology; D006558:Herpes Genitalis / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D018258:Herpesvirus 2, Human / Q000276:immunology; D006801:Humans; D007114:Immunization / Q000379:methods*; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism; D008081:Liposomes / Q000008:administration & dosage / Q000138:chemical synthesis / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010316:Particle Size; D011498:Protein Precursors / Q000008:administration & dosage / Q000276:immunology; D013154:Spleen / Q000276:immunology / Q000378:metabolism; D013501:Surface-Active Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D015320:Tachykinins / Q000008:administration & dosage / Q000276:immunology; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000914:Antibodies, Viral; D016207:Cytokines; D029721:Drosophila Proteins; D022301:Herpes Simplex Virus Vaccines; D007074:Immunoglobulin G; D008081:Liposomes; D011498:Protein Precursors; D013501:Surface-Active Agents; D015320:Tachykinins; C412572:Tk protein, Drosophila; D014759:Viral Envelope Proteins; C562160:glycoprotein B, human herpesvirus 1